title: The oligomer modulator anle138b inhibits disease progression in a Parkinson mouse model even with treatment started after disease onset.
authors.affiliation: Neurologische Klinik, Klinikum der Ludwig-Maximilians-Universität, Munich, Germany.
authors.forename: Johannes
authors.initials: J
authors.lastname: Levin
authors.forename: Felix
authors.initials: F
authors.lastname: Schmidt
authors.forename: Cathrin
authors.initials: C
authors.lastname: Boehm
authors.forename: Catharina
authors.initials: C
authors.lastname: Prix
authors.forename: Kai
authors.initials: K
authors.lastname: Bötzel
authors.forename: Sergey
authors.initials: S
authors.lastname: Ryazanov
authors.forename: Andrei
authors.initials: A
authors.lastname: Leonov
authors.forename: Christian
authors.initials: C
authors.lastname: Griesinger
authors.forename: Armin
authors.initials: A
authors.lastname: Giese
mesh_terms: D000818:Animals; D000978:Antiparkinson Agents / Q000494:pharmacology*; D052117:Benzodioxoles / Q000494:pharmacology*; D001835:Body Weight; D018450:Disease Progression; D018572:Disease-Free Survival; D005260:Female; D008822:Mice, Transgenic; D020734:Parkinsonian Disorders / Q000188:drug therapy* / Q000503:physiopathology; D011720:Pyrazoles / Q000494:pharmacology*; D013997:Time Factors; D051844:alpha-Synuclein / Q000235:genetics / Q000378:metabolism
chemical_list: C000593290:3-(1,3-benzodioxol-5-yl)-5-(3-bromophenyl)-1H-pyrazole; D000978:Antiparkinson Agents; D052117:Benzodioxoles; D011720:Pyrazoles; C497604:SNCA protein, human; D051844:alpha-Synuclein